SUBSCRIBE
SUBSCRIBE

BeiGene

NEWS
Business
BeiGene Shows Off Strong Results from Checkpoint Inhibitor While Eying Potential Approval for BTK Inhibitor
BeiGene is starting off the week with a bang. Late Sunday the company announced positive preliminary topline results from its Phase II trial of tislelizumab, the company’s investigational checkpoint inhibitor for relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL).
July 23, 2018
 · 
3 min read
 · 
Alex Keown
Roche Could Take a $500M Hit Over Patent Losses
Biotech Bay
3 Overlooked Biopharmas Insiders are Snapping Up
A look at three intriguing biotech stocks that are seeing big insider buying from top-ranked insiders right now.
January 30, 2018
 · 
1 min read
Business
How Transformative Is This Licensing Deal For BeiGene?
July 7, 2017
 · 
1 min read
Celgene Cuddles Up With Another Cambridge Biotech, This Time to Tackle Autoimmune Diseases
Business
Biotech Bestie Celgene Takes Stake, Inks $1 Billion+ Deal With BeiGene
July 6, 2017
 · 
3 min read
Business
Medivation Exec Jumps Ship to Become CMO at BeiGene
August 25, 2016
 · 
2 min read
Load More
JOBS
IN THE PRESS
FDA
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
January 19, 2023
 · 
14 min read
Genetown
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
January 19, 2023
 · 
9 min read
Genetown
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
January 18, 2023
 · 
20 min read
Genetown
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
January 17, 2023
 · 
7 min read
Genetown
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
January 4, 2023
 · 
1 min read
Genetown
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
December 30, 2022
 · 
6 min read
Drug Development
BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
December 13, 2022
 · 
9 min read
Genetown
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
December 9, 2022
 · 
7 min read
Genetown
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
November 22, 2022
 · 
11 min read
Genetown
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
November 17, 2022
 · 
10 min read
Load More